New Drugs For Rare Diseases Facing Higher Reimbursement Hurdles
Executive Summary
Drugs and biologics being developed to treat rare diseases, or life-threatening diseases such as cancer and HIV/AIDS are now starting to face the same kind of private payer scrutiny and value-based coverage decisions that were previously reserved for small-molecule drugs entering crowded therapeutic classes
You may also be interested in...
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.